Colon Adenocarcinoma Stage IIA—Can We Predict Relapse?

Pinto, João Cortez; Rosa, Isadora; Martins, Catarina; Marques, Inês; Silva, João Pereira da; Fonseca, Ricardo Roberto de Souza; Freire, João; Pereira, António Dias

doi:10.1007/s12029-019-00218-9

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic benefit of adjuvant chemotherapy in stage II cancer has been controversial in many previous reports. Some reported that a clear OS benefit of adjuvant chemotherapy had not been shown for stage II colon cancer [ 1 14 15 16 17 ], and some studies reported higher survival outcomes of stage II colorectal cancer with adjuvant chemotherapy in subgroups of patients [ 17 18 19 ]. Studies reporting prognostic improvement with adjuvant chemotherapy indicate that this benefit was mainly seen in the subgroup of patients with T4 disease [ 4 20 21 ].…”

Section: Discussionmentioning

confidence: 99%

Can clinicopathologic high-risk features in T3N0 colon cancer be reliable prognostic factors?

et al. 2023

View full text Add to dashboard Cite

Purpose The purpose of this study was to assess the reliability and prognostic significance of the high-risk feature (HRF) in patients with T3N0 colon cancer. Methods We included 1,205 patients with pT3N0 colon cancer treated with curative radical resection between 2012 and 2016. HRF was defined as lymphovascular invasion, perineural invasion, poorly/undifferentiated histology, margin involvement, and preoperative obstruction. We investigated the relationships between the number and type of HRF and recurrence-free survival (RFS) and overall survival (OS), as well as the effect of adjuvant treatment. Results A total of 751 of the patients (62.3%) had more than 1 HRF and 515 of the patients (42.7%) underwent adjuvant treatment. Patients who had more than 2 HRFs had a significantly worse 5-year RFS and OS compared to patients who had neither HRF nor even one HRF. According to the findings of the multivariate analysis, the presence of multiple HRFs was a risk factor for a lower RFS and OS. When the quantity and type of HRF were taken into consideration in the multivariate analysis, adjuvant chemotherapy was not found to be linked with RFS or OS in patients with pT3N0 colon cancer. Conclusion In the present study, adjuvant treatment based on the current guideline of treatment indication was unable to enhance the prognosis of patients with pT3N0 colon cancer. The role of adjuvant treatment in T3N0 colon cancer must be examined with the HRF count in mind.

show abstract

Section: Discussionmentioning

confidence: 99%

Can clinicopathologic high-risk features in T3N0 colon cancer be reliable prognostic factors?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…However, there was a relative lack of research for stage IIA colon cancer. Pinto et al reported on the overall good prognosis and absence of recurrence predictive factors of stage IIA colon cancer and validated the decision of not submitting the patients to chemotherapy risks [30]. However, although stage IIA colon cancer has a relatively good prognosis, 20-25% of patients eventually die of recurrence.…”

Section: Adjuvant Chemotherapy For Stage Iia Colon Cancermentioning

confidence: 99%

Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer

2021

View full text Add to dashboard Cite

There is no clear evidence of the benefit of adjuvant chemotherapy (AC) in stage IIA colon cancer. Therefore, we aimed to evaluate the prognostic factors and survival benefit of AC in this disease. Methods: A retrospective data collection for patients who underwent radical surgery for colon cancer between January 2008 and December 2015 was undertaken. The cohort was divided into No AC and AC groups. Results: We included 227 patients with stage IIA colon cancer in our study cohort, including 67 and 160 patients in the No AC and AC groups, respectively. The number of retrieved lymph nodes and the presence of tumor complications as obstruction or perforation were independent risk factors for survival. In the No AC group, there was a significant difference in survival according to the number of retrieved lymph nodes. In the AC group, there were significant differences in survival according to sidedness and preoperative carcinoembryonic antigen (CEA). There was no significant difference in survival between the No AC and the AC groups. Conclusions: The number of retrieved lymph nodes and the presence of tumor complications were prognostic factors for stage IIA colon cancer but lymphovascular and perineural invasion were not. Sidedness and preoperative CEA could be used as factors to predict the benefit of adjuvant chemotherapy. Currently, it is believed that there is no benefit of AC for stage IIA colon cancer. Further studies are needed to determine the survival benefit of adjuvant chemotherapy in stage IIA colon cancer.

show abstract

“…3 However, CAC patients with advanced stages of disease still possess a worse 5-year survival rate which is <16% because of distant metastasis and limited treatments for these patients. 4,5 Present studies about the mechanisms of CAC metastasis are not clarified yet. Thus, exploring the underly mechanism of CAC development and discovering novel therapies are of great clinical importance for safe and effective treatments, as well as improving the prognosis of CAC patients.…”

mentioning

confidence: 99%

“…Because of the progressions of current treatment and diagnose, the survival rate of CAC has been improved in the recent years 3. However, CAC patients with advanced stages of disease still possess a worse 5-year survival rate which is <16% because of distant metastasis and limited treatments for these patients 4,5. Present studies about the mechanisms of CAC metastasis are not clarified yet.…”

mentioning

confidence: 99%

Elevated Expression of SATB1 Predicts Unfavorable Clinical Outcomes in Colon Adenocarcinoma

Liu

et al. 2022

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Backgrounds: Special AT-rich sequence-binding protein 1 (SATB1) belongs to the chromatin-remodeling protein which regulates different genes expression. High expression of SATB1 was found to be associated with the development of certain carcinomas. However, the functions of SATB1 in colon adenocarcinoma (CAC) remains unclear yet. Our study aims to investigate the potential role of SATB1 in CAC and whether it is associated with the unfavorable symptoms of CAC patients. Methods: The expression pattern of SATB1 was measured in CAC samples and adjacent noncancerous samples through quantitative real-time polymerase chain reaction and immunohistochemistry staining. We performed univariate and multivariate analyses to evaluate the clinical role of SATB1 in enrolled patients. The Kaplan-Meier analyses and log-rank tests were carried out to assess the clinicopathologic characteristics. The effect of SATB1 in human colon cancer cells was examined through cellular experiments. Results: The expression level of SATB1 in CAC tissues was significantly elevated compared with adjacent control tissues. High expression of SATB1 in tumor tissue was found to be associated with lymph node metastasis and advanced TNM stage. Higher SATB1 level in CAC patients indicated a worse 5-year survival time. Moreover, high SATB1 was defined as an independent poor prognostic factor. Cellular experiments showed that inhibition of the SATB1 protein level in human colon cells could suppress the migration and invasion capabilities. Conclusions: Our findings revealed that high expression of SATB1 was significantly correlated with the poor clinical features and prognosis of CAC patients. It indicated that SATB1 might serve as a potential prognostic predictor and novel drug target for CAC treatment.

show abstract

Colon Adenocarcinoma Stage IIA—Can We Predict Relapse?

Cited by 3 publications

References 29 publications

Can clinicopathologic high-risk features in T3N0 colon cancer be reliable prognostic factors?

Can clinicopathologic high-risk features in T3N0 colon cancer be reliable prognostic factors?

Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer

Elevated Expression of SATB1 Predicts Unfavorable Clinical Outcomes in Colon Adenocarcinoma

Contact Info

Product

Resources

About